BR112014029834A2 - polipeptídeo ou um sal, formulação farmacêutica, polipeptídeo ou sal, métodos de determinação se as células t reconhecem um polipeptídeo ou sal, de tratamento de um indivíduo ou de prevenção de uma alergia em um indivíduo a cladosporium e/ou alternaria, e para preparar uma formulação farmacêutica, e, uso de um polipeptídeo ou sal - Google Patents

polipeptídeo ou um sal, formulação farmacêutica, polipeptídeo ou sal, métodos de determinação se as células t reconhecem um polipeptídeo ou sal, de tratamento de um indivíduo ou de prevenção de uma alergia em um indivíduo a cladosporium e/ou alternaria, e para preparar uma formulação farmacêutica, e, uso de um polipeptídeo ou sal

Info

Publication number
BR112014029834A2
BR112014029834A2 BR112014029834A BR112014029834A BR112014029834A2 BR 112014029834 A2 BR112014029834 A2 BR 112014029834A2 BR 112014029834 A BR112014029834 A BR 112014029834A BR 112014029834 A BR112014029834 A BR 112014029834A BR 112014029834 A2 BR112014029834 A2 BR 112014029834A2
Authority
BR
Brazil
Prior art keywords
polypeptide
salt
individual
pharmaceutical formulation
seq
Prior art date
Application number
BR112014029834A
Other languages
English (en)
Inventor
Larche Mark
Hickey Pascal
Laidler Paul
Peter Hafner Roderick
Original Assignee
Circassia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Circassia Ltd filed Critical Circassia Ltd
Publication of BR112014029834A2 publication Critical patent/BR112014029834A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01138—Mannitol 2-dehydrogenase (NADP+) (1.1.1.138)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C12Y102/01003—Aldehyde dehydrogenase (NAD+) (1.2.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01011—Phosphopyruvate hydratase (4.2.1.11), i.e. enolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

1 / 1 resumo “polipeptãdeo ou um sal, formulaã‡ãƒo farmacãšutica, polipeptãdeo ou sal, mã‰todos de determinaã‡ãƒo se as cã‰lulas t reconhecem um polipeptãdeo ou sal, de tratamento de um indivãduo ou de prevenã‡ãƒo de uma alergia em um indivãduo a cladosporium e/ou alternaria, e para preparar uma formulaã‡ãƒo farmacãšutica, e, uso de um polipeptãdeo ou sal” polipeptã­deos que podem ser usados para a prevenã§ã£o ou tratamento de alergia aos mofos dos gãªneros cladosporium e/ou alternaria, tãªm atã© 30 aminoã¡cidos de comprimento e compreendem: (i) a sequãªncia de aminoã¡cidos: (a) ggykaavrptmle (seq id no: 35; cla35), (b) aevyqklksltkk (seq id no: 31; cla16), (c) vaityasraqgae (seq id no: 32; cla25), (d) ghhfkergtgslvit (seq id no: 33; cla26), ou (e) anytqtktvsirl (seq id no: 34; cla29); ou (ii) uma sequãªncia variante contendo epã­topo de cã©lulas t que ã© uma referida sequãªncia de aminoã¡cidos (i) tendo atã© seis modificaã§ãµes de aminoã¡cido, cada sendo independentemente uma deleã§ã£o, substituiã§ã£o ou inserã§ã£o.
BR112014029834A 2012-06-01 2013-05-30 polipeptídeo ou um sal, formulação farmacêutica, polipeptídeo ou sal, métodos de determinação se as células t reconhecem um polipeptídeo ou sal, de tratamento de um indivíduo ou de prevenção de uma alergia em um indivíduo a cladosporium e/ou alternaria, e para preparar uma formulação farmacêutica, e, uso de um polipeptídeo ou sal BR112014029834A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1209862.0A GB201209862D0 (en) 2012-06-01 2012-06-01 Cladosporium peptides
PCT/GB2013/051440 WO2013179044A2 (en) 2012-06-01 2013-05-30 Cladosporium peptides

Publications (1)

Publication Number Publication Date
BR112014029834A2 true BR112014029834A2 (pt) 2017-07-25

Family

ID=46582262

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014029834A BR112014029834A2 (pt) 2012-06-01 2013-05-30 polipeptídeo ou um sal, formulação farmacêutica, polipeptídeo ou sal, métodos de determinação se as células t reconhecem um polipeptídeo ou sal, de tratamento de um indivíduo ou de prevenção de uma alergia em um indivíduo a cladosporium e/ou alternaria, e para preparar uma formulação farmacêutica, e, uso de um polipeptídeo ou sal

Country Status (16)

Country Link
US (1) US9850281B2 (pt)
EP (1) EP2855514A2 (pt)
JP (1) JP2015520171A (pt)
KR (1) KR20150016622A (pt)
CN (1) CN104507960A (pt)
AU (1) AU2013269327A1 (pt)
BR (1) BR112014029834A2 (pt)
CA (1) CA2875131A1 (pt)
CL (1) CL2014003289A1 (pt)
EA (1) EA201492270A1 (pt)
GB (2) GB201209862D0 (pt)
HK (1) HK1202554A1 (pt)
IL (1) IL235842A0 (pt)
MX (1) MX2014014460A (pt)
SG (1) SG11201407945SA (pt)
WO (1) WO2013179044A2 (pt)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT400722B (de) * 1993-08-27 1996-03-25 Biomay Prod & Handel Rekombinante cladosporium herbarum allergene
AT401181B (de) 1994-11-02 1996-07-25 Biomay Prod & Handel Rekombinante dna moleküle
AT403166B (de) * 1995-03-02 1997-11-25 Biomay Prod & Handel Rekombinante dna moleküle, die für polypeptide kodieren, die die antigenität der allergene clah8 und clah12 besitzen
CA2217173C (en) 1997-11-25 2008-04-01 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Health Isolation of a cdna clone encoding a subunit of the alternaria alternata major allergen alt a 1, and production of recombinant protein thereof
US7247441B2 (en) 2002-03-28 2007-07-24 Biomay Produktions- Und Handels-Aktienge Sellschaft Nucleic acid sequence and protein in addition to polypeptides coding for mannitol dehydrogenases or parts thereof and the production and use thereof in diagnosis and therapy
PL2083856T3 (pl) 2007-08-15 2011-04-29 Circassia Ltd Peptydy do odczulania na alergeny
CN101178406A (zh) 2007-12-05 2008-05-14 杭州浙大生物基因工程有限公司 过敏原特异性抗体IgE ELISA检测试剂盒及其制备方法
JP5705113B2 (ja) * 2008-08-15 2015-04-22 サーカッシア リミテッド Ｉｌ−１０産生の刺激のためのアレルゲン由来のｔ細胞抗原
CN101387643A (zh) 2008-10-20 2009-03-18 杭州浙大生物基因工程有限公司 多通道过敏原快速检测试剂盒及其制备方法
CN101393215A (zh) 2008-11-17 2009-03-25 杭州浙大生物基因工程有限公司 多通道吸入型过敏原快速检测试剂盒及其制备方法
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
GB201002559D0 (en) 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine
CN102212531A (zh) 2010-04-02 2011-10-12 复旦大学 一种重组多主枝孢霉变应原Cla h8蛋白的制备方法及其用途
KR20130118884A (ko) 2010-10-15 2013-10-30 알크-아벨로 에이/에스 알레르겐 소스 물질로부터 유도된 무관련 알레르겐을 이용한 과민성 면역반응의 억제
WO2013119853A1 (en) * 2012-02-07 2013-08-15 La Jolla Institute For Allergy And Immunology Epitopes from allergen proteins and methods and uses for immune response modulation

Also Published As

Publication number Publication date
WO2013179044A3 (en) 2014-03-06
US9850281B2 (en) 2017-12-26
WO2013179044A2 (en) 2013-12-05
EP2855514A2 (en) 2015-04-08
US20150218215A1 (en) 2015-08-06
JP2015520171A (ja) 2015-07-16
IL235842A0 (en) 2015-01-29
MX2014014460A (es) 2015-02-12
KR20150016622A (ko) 2015-02-12
AU2013269327A1 (en) 2014-12-18
HK1202554A1 (en) 2015-10-02
CN104507960A (zh) 2015-04-08
CL2014003289A1 (es) 2015-05-22
GB201209862D0 (en) 2012-07-18
CA2875131A1 (en) 2013-12-05
EA201492270A1 (ru) 2015-09-30
GB2518092A (en) 2015-03-11
SG11201407945SA (en) 2014-12-30

Similar Documents

Publication Publication Date Title
CL2018000232A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
MX2023003875A (es) Formulacion de una vacuna peptidica.
BR112018071466A2 (pt) novos peptídeos de ligação a cd1d imunogênicos
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
BR112018000632A2 (pt) moléculas de anticorpo que ligam a cd79
BR112017019343A2 (pt) uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas
WO2015020913A3 (en) Influenza hemagglutinin proteins and methods of thereof
AR102445A1 (es) COMPOSICIONES Y MÉTODOS RELACIONADOS CON b-GLUCOSIDASA
BR112015009280A2 (pt) preparações liofilizadas de melfalana flufenamida
CL2017003066A1 (es) Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal
BR112017013453A2 (pt) novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório
ES2671434T3 (es) Antagonistas de Kv1.3 y métodos de uso
BR112013013548B8 (pt) Proteína de fusão anticancerígena
EA201491277A1 (ru) Противораковый слитый белок
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
BR112017013300A2 (pt) alfa galactosidase a recombinante e/ou fragmento de alfa galactosidase a recombinante biologicamente ativo, composição, sequência de polinucleotídeos recombinantes, vetor de expressão, célula hospedeira, métodos para produzir uma variante de alfa galactosidase a e para tratar e/ou prevenir os sintomas da doença de fabry, composição farmacêutica, e, uso das composições.
BR112013019513A2 (pt) métodos para o tratamento de úlceras diabéticas do pé
BR112014023572A2 (pt) método para tratar ou prevenir dano de articulação em um indivíduo com ra precoce ou ra incipiente, uso de um agente ou combinação de agentes que estimulam uma resposta tolerogênica específica de antígeno a um polipeptídeo de agrecan, e agente ou combinação de agentes
BR112015030355A8 (pt) uso de uma proteína ou um polipeptídeo de adenilil ciclase tipo 6 (ac6) incompetente com a adenosina monofosfato cíclico (incompetente com camp) ou um gene ou ácido nucléico que codifica ac6mut, e, formulação
TR201910117T4 (tr) OspA nın mutant fragmanları ve bunlara ilişkin yöntemler ve kullanımları.
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
BR112015019568A2 (pt) Peptídeo isolado, composição compreendendo o mesmo e uso do mesmo
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
BR112017006969A2 (pt) peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2465 DE 03-04-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]